"Novo Nordisk Anticipates Wegovy Approval in China in 2022"

Novo Nordisk expects its weight-loss drug Wegovy, also known as semaglutide, to be approved in China this year and plans to launch it with capped volumes, focusing on patients paying out-of-pocket initially. The drug belongs to a class of drugs known as GLP-1s, used to treat obesity and diabetes. The company's main competitor in this arena is Eli Lilly, with other companies also developing GLP-1 drugs.